- Home
- DLPN vs BLRX Comparison
DLPN vs BLRX Comparison
Compare DLPN & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLPN
- BLRX
- Stock Information
- Founded
- DLPN 1996
- BLRX 2003
- Country
- DLPN United States
- BLRX Israel
- Employees
- DLPN N/A
- BLRX N/A
- Industry
- DLPN Other Consumer Services
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- DLPN Consumer Discretionary
- BLRX Health Care
- Exchange
- DLPN Nasdaq
- BLRX Nasdaq
- Market Cap
- DLPN 11.4M
- BLRX 11.9M
- IPO Year
- DLPN N/A
- BLRX 2011
- Fundamental
- Price
- DLPN $1.09
- BLRX $3.17
- Analyst Decision
- DLPN Strong Buy
- BLRX Buy
- Analyst Count
- DLPN 1
- BLRX 2
- Target Price
- DLPN $5.00
- BLRX $26.00
- AVG Volume (30 Days)
- DLPN 12.9K
- BLRX 18.9K
- Earning Date
- DLPN 05-20-2025
- BLRX 05-27-2025
- Dividend Yield
- DLPN N/A
- BLRX N/A
- EPS Growth
- DLPN N/A
- BLRX N/A
- EPS
- DLPN N/A
- BLRX N/A
- Revenue
- DLPN $51,684,984.00
- BLRX $28,940,000.00
- Revenue This Year
- DLPN $2.62
- BLRX N/A
- Revenue Next Year
- DLPN $22.65
- BLRX N/A
- P/E Ratio
- DLPN N/A
- BLRX N/A
- Revenue Growth
- DLPN 19.86
- BLRX 502.92
- 52 Week Low
- DLPN $0.75
- BLRX $2.30
- 52 Week High
- DLPN $2.78
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- DLPN 54.86
- BLRX 51.14
- Support Level
- DLPN $1.00
- BLRX $3.13
- Resistance Level
- DLPN $1.16
- BLRX $3.09
- Average True Range (ATR)
- DLPN 0.06
- BLRX 0.18
- MACD
- DLPN 0.00
- BLRX 0.02
- Stochastic Oscillator
- DLPN 58.76
- BLRX 50.77
About DLPN Dolphin Entertainment Inc.
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.